Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Celcuity LLC
CELCCurrent price
10.24 USD
+0.3 USD (+3.02%)
Last closed
9.16 USD
Company
www.celcuity.com
ISIN
US15102K1007
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
327 310 784 USD
Yield for 12 month
-37.52 %
1Y
3Y
5Y
10Y
15Y
CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota. Address: 16305 36th Avenue North, Minneapolis, MN, United States, 55446
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
30.43 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-142 772 USD
Current Quarter
–
Last Quarter
–
Key Figures CELC
1 year
3 years
5 years
10 years
EBITDA
-113 137 008 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-32.45 %
PEG Ratio
–
Return On Equity TTM
-87.54 %
Wall Street Target Price
30.43 USD
Revenue TTM
–
Book Value
3.11 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.83 USD
Diluted Eps TTM
-2.83 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CELC
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CELC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation CELC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-7.80
Price Book MRQ
2.83
Financials CELC
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CELC
For 52 weeks
7.58 USD
19.77 USD
50 Day MA
10.75 USD
Shares Short Prior Month
3 250 391
200 Day MA
13.86 USD
Short Ratio
11.25
Shares Short
3 104 996
Short Percent
10.01 %
BeatStart